Kelvin Chou, MD
Alexander S and Gabriella Karp Professor of Neurology
Clinical Professor of Neurology
Clinical Professor of Neurosurgery
Associate Chair for Faculty Development and Section Head for Co-Division Chief Movement
Department of Neurology
2901 Hubbard Road, Suite 2723
Ann Arbor, MI 48109
[email protected]

Available to mentor

Kelvin Chou, MD
Clinical Professor
  • About
  • Qualifications
  • Research Overview
  • Recent Publications
  • About

    Kelvin L. Chou, M.D. is the Alexander S. and Gabriella Karp Professor of Neurology at the University of Michigan. He also serves as Co-Director of the Parkinson’s Disease and Movement Disorders Division and Associate Chair of Faculty Development in Neurology. Dr. Chou has been named to the Best Doctors of America list since 2011 and has clinical expertise and research interests in Parkinson’s disease (PD) and deep brain stimulation (DBS).

    Dr. Chou serves as Co-Director of the STIM (Surgical Therapies Improving Movement) Program with a research focus on improving the ability to treat movement disorders patients through DBS. He is also an experienced clinical trialist, conducting numerous clinical trials on new therapies for PD, essential tremor and Huntington disease. He has published over 100 peer-reviewed journal articles, review articles or book chapters on PD and related movement disorders and serves on the editorial board for Neurology and Parkinsonism and Related Disorders.

    A strong patient advocate, Dr. Chou serves on the Professional Advisory Board of the Michigan Parkinson Foundation and the Medical Advisory Board of the International Essential Tremor Foundation (IETF). He has also authored a book for patients and families called Deep Brain Stimulation: A New Life for People with Parkinson's, Dystonia and Essential Tremor.

    Qualifications
    • MD
      University of Michigan Medical School, M4101 MSI Box 0624 1301 Catherine, 1998
    • BS
      University of Michigan, Ann Arbor, 1995
    Research Overview

    • Deep brain stimulation for Parkinson’s disease, Essential Tremor, and other movement disorders
    • Experimental therapeutics for Parkinson’s disease, Essential Tremor and other movement disorders
    • Non-motor and motor aspects of Parkinson’s disease

    Recent Publications See All Publications
    • Presentation
      "PPMI Updates: What can these data tell us about disease staging, treatment development now and in the future, and prognosis?"
      2024 Dec 6;
    • Additional Scholarship
      Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study over 12 months.
      Adams JL, Kangarloo T, Gong Y, Khachadourian V, Tracey B, Volfson D, Latzman RD, Cosman J, Edgerton J, Anderson D, Best A, Kostrzebski MA, Auinger P, Wilmot P, Pohlson Y, Jensen-Roberts S, Müller MLTM, Stephenson D, Dorsey ER, Parkinson Study Group Watch-PD Study Investigators and Collaborators . NPJ Parkinsons Dis, 2024 Jun 12; 10 (1): 112 DOI:10.1038/s41531-024-00721-2
      PMID: 38866793
    • Presentation
      "A Prescription for Better Parkinson's Disease Care"
      Chou K. 2024 Nov 12;
    • Presentation
      DBS System Programming Workshop and Advancements in Digital Health
      Chou K, Lotia M, Imbus A. 2024 Oct 26;
    • Presentation
      DBS System Programming Workshop and Advancements in Digital Health
      Chou K, Lotia M, Imbus A. 2024 Oct 26;
    • Proceeding / Abstract / Poster
      ID: 317152 Intraoperative Functional Mapping with Deep Brain Stimulation Local Evoked Potentials in Awake and Anesthetized States
      Bence E, Engelhardt W, Mantena N, Gadzic E, Miocinovic S, Brunner P, Willie J, Heston A, Chen K, Levin E, Chou K, Leventhal D, Opri E. Neuromodulation Technology at the Neural Interface, 2024 Jan 18; 27 (7): s174 - s175. DOI:10.1016/j.neurom.2024.06.319
    • Proceeding / Abstract / Poster
      ID: 335187 Optimal Locations for Levodopa and Dyskinesia Reduction in Subthalamic Deep Brain Stimulation for Parkinson Disease
      Hall V, Chou K, Patil P, Malaga K. Neuromodulation Technology at the Neural Interface, 2024 Jan 18; 27 (7): s231 - s231. DOI:10.1016/j.neurom.2024.06.411
    • Additional Scholarship
      Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
      Dam T, Pagano G, Brumm MC, Gochanour C, Poston KL, Weintraub D, Chahine LM, Coffey C, Tanner CM, Kopil CM, Xiao Y, Chowdhury S, Concha-Marambio L, DiBiaso P, Foroud T, Frasier M, Jennings D, Kieburtz K, Merchant K, Mollenhauer B, Montine TJ, Nudelman K, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Siderowf A, Dunn B, Simuni T, Marek K, Parkinson’s Progression Markers Initiative . NPJ Parkinsons Dis, 2024 Sep 27; 10 (1): 178 DOI:10.1038/s41531-024-00789-w
      PMID: 39333167
    Featured News & Stories
    Department News
    Why physicians need to consider the patient’s perspective
    Why physicians need to consider the patient’s perspective